Lentitag: a novel approach to the efficient manufacturing of active lentiviral vectors
Ended Project Grant Awarded Last action
- Award ID
- R43GM144018
- Recipient
-
Isolere Bio Inc. UEI U9LXLSXNME74
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $511,112
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Cell and gene therapies are garnering attention for their remarkable clinical outcomes and their promise to treat diseases previously considered uncurable. Lentiviral vectors (LVS) are used in over one third of applications in cell and gene therapies.2 as with most viral vector and vaccine manufacturing, LVS are challenging and expensive to manufacture and there are no methods in commercial use that offer specificity, high yield, and scalability. Current manufacturing relies on anion exchange chromatography, which (1) has poor capacities for large viruses that cannot effectively diffuse into small resin pores, (2) necessitates additional purification steps because its lack of LV specificity causes contaminant CO-purification, and (3) requires harsh elution conditions that result in low infectious LV recoveries of only ~50%.15, 1 in this phase i sbir proposal, isolere BIO will develop a fusion protein reagent comprised of an affinity domain that is specific for LV and a proprietary biopolymer domain that has robust and precisely tunable liquid-liquid phase separation behavior. The lentitag™ reagent will capture LVS in solution with high specificity and then efficiently sequester them into phase separated droplets on command with a simple environmental trigger - an incremental adjustment in salt. These droplets, highly pure and concentrated, are easily separated from all excluded contaminants with tangential flow filtration (TFF), a unit operation that scales up simply and enables high volumetric throughput. Once host cell proteins and other cellular contaminants have been washed away, the LV can be gently recovered from the droplets with an elution buffer that disrupts the affinity interaction at near-neutral PH. To demonstrate lentitag™'s technical feasibility, isolere will first design, produce, and characterize an LV-specific capture protein (LCP). The LCP binds the most common LV envelope glycoprotein and phase separates at ambient temperature with a small increase in salt (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $255,556 | |
| Original award | $255,556 |
Quick answers
Who received award R43GM144018?
R43GM144018 was awarded to Isolere Bio Inc. by National Institute of General Medical Sciences (National Institutes of Health) on February 1, 2022.
How much is award R43GM144018 worth?
$511,112 has been obligated on R43GM144018.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award